Fingolimodis an immunomodulating drug, indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Cadila Healthcare that it has received tentative approval from the USFDA to market fingolimod capsules in the strength of 0.25 mg. The drug is the bioequivalent of US reference listed drug (RLD) Gilenya capsules.
In October 2020, the group was granted approval to market fingolimod capsules in the strength of 0.5 mg.
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Also Read
The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The scrip fell 1.13% to currently trade at Rs 617.30 on the BSE.
In the past three months, the stock has zoomed 43.23% while the benchmark Sensex has added 6.93% during the same period.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
